NImmune Biopharma, Inc
Raquel Hontecillas is a seasoned scientific leader with extensive experience in biopharma and academia. Currently serving as Chief Scientific Officer at NImmune Biopharma, Inc. since March 2023, Raquel also holds the position of Chief Scientific Officer at The NIMML Institute since June 2002. Previous roles include Chief Scientific Officer at Landos Biopharma, Inc. from April 2017 to April 2022 and a professorship at Virginia Tech from August 2008 to July 2020. Raquel's career demonstrates a strong commitment to advancing scientific knowledge and innovation in the field.
This person is not in any teams
NImmune Biopharma, Inc
NImmune is a late-stage precision immunology biopharmaceutical company that develops best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by advanced computational modeling and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. NImmune’s clinical development pipeline includes omilancor, a Phase 3-ready lead clinical candidate targeting LANCL2, an oral, once-daily, gut-restricted, first-in-class therapeutic for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2023.